Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL Financing complements the…
January 7 – 10, 2019 J.P. Morgan 37th Annual Healthcare Conference 2019 San-Francisco The annual J.P. Morgan Healthcare Conference is the largest and most…
Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…
The immune system is able to recognize tumor cells and destroy them…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
